Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 104

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 104
---
ARS-CoV-2 and West Nile Virus (WNV) antigens. These studies showed promising immunogenicity
and protection outcomes in rodent models and demonstrated the platform’s modularity across viral targets.

Planned Patent Applications and Timeline

Assuming the success of the animal study and
our positive determination of the commercial viability of the protein based vaccine, we plan to submit new provisional applications for
the novel approach and related components of the technology and for the delivery of specific proteins targeting chosen viruses are being
prepared by the company using all research data results.

As the Company advances its understanding
of the platform’s performance, it is preparing to file new patent applications covering the co-encapsulation of specific protein
combinations targeting additional viruses, including SARS-CoV-2 and WNV. The new patent applications will focus on the antigen-specific
compositions and immunization methods that are not covered by the original CCS delivery patents. These applications are expected to be
submitted following completion and internal review of the final reports from both the West Nile Virus (WNV) and SARS-CoV-2 preclinical
proof-of-concept and challenge studies. These studies are designed to validate the underlying platform and antigen design strategy and
are currently being finalized by Prof. Barenholz’s team. Filings are anticipated by Q4 2025. The key remaining milestones include:
(i) completion and analysis of the SARS-CoV-2 challenge study dataset, and (ii) drafting of patent claims specific to each antigen formulation.
In addition, we are planning to submit new patent applications.

Our liposomal vaccine platform is designed
to co-encapsulate multiple recombinant protein antigens within a proprietary lipid nanoparticle system incorporating ceramide carbamoyl
spermine (CCS), a synthetic lipid developed to enhance immunogenicity, antigen stability, and mucosal delivery. This platform has been
evaluated in preclinical models for two viral targets: SARS-CoV-2 and West Nile Virus (WNV). The dual-antigen design includes the receptor
binding domain (RBD) and nucleocapsid (N) proteins for SARS-CoV-2, and the EDIII and NS1 proteins for WNV, offering both neutralizing
antibody and T-cell mediated immune responses.

<div align='center'>64</div>

Current Stage of Development:

The vaccine candidates have completed preclinical
proof-of-concept studies in rodent models. A BSL-3 challenge